Non--Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Molina, Julian R.; Ping Yang; Cassivi, Stephen D.; Schild, Steven E.; Adjei, Alex A.
May 2008
Mayo Clinic Proceedings;May2008, Vol. 83 Issue 5, p584
Academic Journal
Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world. In North America, lung cancer has become more predominant among former than current smokers. Yet in some countries, such as China, which has experienced a dramatic increase in the cigarette smoking rate during the past 2 decades, a peak in lung cancer incidence is still expected. Approximately two-thirds of adult Chinese men are smokers, representing one-third of all smokers worldwide. Non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States. After the initial diagnosis, accurate staging of non-small cell lung cancer using computed tomography or positron emission tomography Is crucial for determining appropriate therapy. When feasible, surgical resection remains the single most consistent and successful option for cure. However, close to 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis. Chemotherapy is beneficial for patients with metastatic disease, and the administration of concurrent chemotherapy and radiation is indicated for stage Ill lung cancer. The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors. We identified studies for this review by searching the MEDLINE and PubMed databases for English-language articles published from January 1, 1980, through January 31, 2008. Key terms used for this search included non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, large cell carcinoma, lung cancer epidemiology, genetics, survivorship, surgery, radiation therapy, chemotherapy, targeted therapy, bevacizumab, eriotinib, and epidermal growth factor receptor.


Related Articles

  • Acrometastasis from squamous cell lung cancer. Chih-Cheng Lai; Che-Kim Tan; Jin-Yuan Shih // CMAJ: Canadian Medical Association Journal;7/31/2007, Vol. 177 Issue 3, p249 

    The article discusses a case of acrometastasis from squamous cell lung cancer in a patient who was a heavy smoker and had a dry cough. He had experienced an unintentional 4 kilogram-weight loss in the two months before presentation. The results of a radiograph, a bone scan, and a chest...

  • Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy. Qiushi Wang; Yong He; Xin Yang; Yubo Wang; Hualiang Xiao // BMC Pulmonary Medicine;2014, Vol. 14 Issue 1, p2 

    Background The discovery of the fusion gene echinodermmicro tubule associated proteinlike 4-anaplastic lymphoma kinase, EML4-ALK, in patients with non-small-cell lung cancer has led to the remarkable development of anaplastic lymphoma kinase inhibitors, such as crizotinib. Consequently, the...

  • Bevacizumab.  // Reactions Weekly;10/6/2012, Issue 1422, p13 

    The article describes a case of posterior reversible encephalopathy syndrome in a 31-year-old woman that developed while receiving bevacizumab for metastatic high grade ovarian squamous cell carcinoma.

  • LUNG CANCER DRUG MAY HELP TREAT ORAL CANCER.  // Journal of the American Dental Association (JADA);Feb2004, Vol. 135 Issue 2, p152 

    Reports on the possibility of using Gefitinib, a drug approved to treat advanced non-small-cell lung cancer in patients who have received chemotherapy, to treat oral cancer. Process by which the drug helps treat cancer; Effect of Gefitinib on patient response to radiotherapy in oropharyngeal...

  • Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma. Sekine, I.; Nokihara, H.; Horiike, A.; Yamamoto, N.; Kunitoh, H.; Ohe, Y.; Tamura, T.; Kodama, T.; Saijo, N. // British Journal of Cancer;3/22/2004, Vol. 90 Issue 6, p1125 

    The recommended phase II dose of paclitaxel 180?mg?m-2 given as a 3-h infusion followed by nedaplatin 100?mg?m-2 in a 1-h infusion every 3-4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%.British...

  • Prognostic Significance of Vitamin D Receptor Polymorphisms in Head and Neck Squamous Cell Carcinoma. Hama, Takanori; Norizoe, Chihiro; Suga, Hiroaki; Mimura, Takeshi; Takakuni Kato; Moriyama, Hiroshi; Urashima, Mitsuyoshi // PLoS ONE;2011, Vol. 6 Issue 12, p1 

    Background: In patients with advanced non-small-cell lung cancer, vitamin D receptor (VDR) polymorphisms and haplotypes are reported to be associated with survival. We hypothesized that a similar association would be observed in patients with head and neck squamous-cell carcinoma (HNSCC)....

  • Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy? Clements, Karen M.; Peltz, Gerson; Faries, Douglas E.; Lang, Kathleen; Nyambose, Joshua; Earle, Craig C.; Sugarman, Katherine P.; Taylor, Douglas C. A.; Thompson, David; Marciniak, Martin D. // Chemotherapy Research & Practice;2010, p1 

    Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of patients (N = 2,644) with stage IIIB/IV NSCLC who received first-line cisplatin/carboplatin plus gemcitabine (C/C+G) and...

  • The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients. Hye-Ryoun Kim; Min Soo Kang; Im Il Na; Sung Hyeon Yang; Yoon Hee Choi; Hye Jin Kang; Cheol Hyeon Kim; Jae Cheol Lee // Journal of Cancer Research & Clinical Oncology;Apr2010, Vol. 136 Issue 4, p547 

    Pemetrexed is a recognized active agent for the second-line treatment for advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the clinical benefits of pemetrexed and to identify patient characteristics that predict response to pemetrexed. We retrospectively...

  • ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Besse, B.; Massard, C.; Haddad, V.; Andre, F.; Dunant, A.; Pirker, R.; Olaussen, K. A.; Brambilla, E.; Fouret, P.; Soria, J. C. // Annals of Oncology;Mar2011, Vol. 22 Issue 3, p575 

    Background: We recently demonstrated that excision repair cross-complementing group 1 protein (ERCC1) is predictive of adjuvant cisplatin-based chemotherapy benefit in resected non-small-cell lung cancer (NSCLC). Non-squamous cell carcinomas (non-SCCs) carry an increased risk of brain metastases...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics